Quantum Computational Quantification of Protein-Ligand Interactions

ORAL

Abstract

A prototypical hybrid classical and quantum computational tools stack for the quantification of protein-ligand interactions is presented herein by using binding energy differences to rank-order a series of β-secretase (BACE1) inhibitors. Due to the large Hilbert space involved, the combination of QM/MM and Density Matrix Embedding Theory (DMET) procedure involving reduced active orbital space with the Variational Quantum Eigensolver (VQE) approach is proven to be effective for finding the ground states of such complex systems. To reduce the device-induced noise, two different techniques were employed: (i) the State Preparation and Measurement (SPAM) error mitigation and (ii) a new flavour of Symmetry Verification approach, the in-house developed Partition Measurement Symmetry Verification (PMSV) algorithm, which is unique in the sense that it does not require any extra quantum resources. The experiments were conducted on the latest superconducting transmon (IBM) and trapped-ion (Honeywell) Noisy Intermediate Scale Quantum (NISQ) devices. This is the first application of real quantum computers to the calculation of protein-ligand interaction. The results shed light on hardware and software requirements which would enable the application of NISQ algorithms in drug design.

*The state-vector simulations in this work were performed on Microsoft Azure Virtual Machines provided by the "Microsoft for Startups" program.

Publication: Quantum Computational Quantification of Protein-Ligand Interactions
JJM Kirsopp, C Di Paola, DZ Manrique, M Krompiec, G Greene-Diniz, W Guba, A Meyder, D Wolf, M Strahm, D Muñoz Ramo
arXiv preprint arXiv:2110.08163

Presenters

  • Cono Di Paola

    • Cambridge Quantum Computing

Authors

  • Cono Di Paola

    • Cambridge Quantum Computing
  • Josh J Kirsopp

    • Cambridge Quantum Computing
  • David Zsolt Manrique

    • Cambridge Quantum Computing
  • Michal Krompiec

    • Cambridge Quantum Computing
  • Gabriel Greene-Diniz

    • Cambridge Quantum Computing
  • Wolfgang Guba

    • Roche Pharmaceutical Research & Early Development
  • Agnes Meyder

    • Roche Pharmaceutical Research & Early Development
  • Detlef Wolf

    • Roche Pharmaceutical Research & Early Development
  • Martin Strahm

    • Roche Pharmaceutical Research & Early Development
  • David Munoz Ramo

    • Cambridge Quantum Computing Ltd., Cambridge CB2 1UB, United Kingdom
    • Cambridge Quantum Computing